Early-Stage pancreatic cancer drug trial halted after just one patient
NCT ID NCT06069778
Summary
This study aimed to see if adding an experimental drug called BNT321 to standard chemotherapy (mFOLFIRINOX) could better prevent pancreatic cancer from returning after surgery. It was designed for patients who had their tumor completely removed. The sponsor stopped the trial early for business reasons, not safety, after only one person was enrolled, so no results are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina (MUSC)
Charleston, South Carolina, 29425, United States
-
Valkyrie Clinical Trials
Los Angeles, California, 90067, United States
Conditions
Explore the condition pages connected to this study.